Reported settlement of around $25 million significantly reduces company funds.
Agreement could cost Theranos $30 million – significantly less than original $140 million lawsuit.
Firm also agrees not to own or operate a lab within two years.
CMS report describes failures meeting its own quality control procedures.
Platform combines morphology analysis, cell counting and cell classification.
Walgreens claims to have been continually misled over Theranos’ technology.